Literature DB >> 15934954

Chronic nicotine differentially affects the function of nicotinic receptor subtypes regulating neurotransmitter release.

Massimo Grilli1, Monica Parodi, Maurizio Raiteri, Mario Marchi.   

Abstract

It is known that nicotine can activate several subtypes of release-regulating presynaptic nicotinic receptors (nAChRs) including those situated on central noradrenergic, dopaminergic, cholinergic and glutamatergic axon terminals. The objective of this study was to investigate the effects of chronic administration of (-)nicotine on the function of the above autoreceptors and heteroreceptors using rat superfused synaptosomes. In hippocampal synaptosomes prelabelled with [3H]noradrenaline (NA) the nicotine-evoked overflow of [3H]NA was higher in rats treated with nicotine for 10 days (via osmotic mini-pumps) than in vehicle-treated rats. In striatal synaptosomes, prelabelled with [3H]dopamine (DA), chronic nicotine did not modify the releasing effect of nicotine. No significant change was observed in experiments with synaptosomes from nucleus accumbens prelabelled with [3H]DA. Exposure of hippocampal synaptosomes prelabelled with [3H]choline to nicotine elicited release of [3H]acetylcholine; this effect was almost abolished in synaptosomes from animals administered nicotine for 10 days, suggesting down-regulation of nicotinic autoreceptors. In hippocampal synaptosomes prelabelled with [3H]D-aspartate, the releasing effect of epibatidine following chronic nicotine treatment did not differ from that in controls. The K+-evoked exocytotic release of the neurotransmitters tested was not modified by long-term nicotine administration. The results show that chronic nicotine differentially affects the function of release-regulating nAChR subtypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15934954     DOI: 10.1111/j.1471-4159.2005.03126.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

1.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

Review 2.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  In vivo effects of the anatoxin-a on striatal dopamine release.

Authors:  F Campos; R Durán; L Vidal; L R F Faro; M Alfonso
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

4.  Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning.

Authors:  Jennifer A Davis; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

Review 5.  Cellular events in nicotine addiction.

Authors:  Rachel E Penton; Robin A J Lester
Journal:  Semin Cell Dev Biol       Date:  2009-01-20       Impact factor: 7.727

6.  Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain.

Authors:  M Grilli; L Raiteri; L Patti; M Parodi; F Robino; M Raiteri; M Marchi
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

7.  Nicotine modulates the renin-angiotensin system of cultured neurons and glial cells from cardiovascular brain areas of Wistar Kyoto and spontaneously hypertensive rats.

Authors:  Merari F R Ferrari; Mohan K Raizada; Debora R Fior-Chadi
Journal:  J Mol Neurosci       Date:  2007-09-25       Impact factor: 3.444

Review 8.  Prenatal nicotine exposure and development of nicotinic and fast amino acid-mediated neurotransmission in the control of breathing.

Authors:  Ralph F Fregosi; Jason Q Pilarski
Journal:  Respir Physiol Neurobiol       Date:  2008-12-10       Impact factor: 1.931

9.  Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Sharon R Grady; Maryka Quik
Journal:  Mol Pharmacol       Date:  2008-06-26       Impact factor: 4.436

10.  r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.

Authors:  Joshua S Beckmann; Andrew C Meyer; M Pivavarchyk; David B Horton; Guangrong Zheng; Andrew M Smith; Thomas E Wooters; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Neurochem Res       Date:  2015-07-31       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.